Earnings Feed
Start Free
Gossamer Bio, Inc.·4

Mar 20, 4:20 PM ET

Peterson Caryn 4

4 · Gossamer Bio, Inc. · Filed Mar 20, 2026

Research Summary

AI-generated summary of this filing

Updated

Gossamer Bio (GOSS) EVP Caryn Peterson Receives Repriced Option Awards

What Happened

  • Caryn Peterson, EVP of Regulatory Affairs at Gossamer Bio, did not buy or sell company stock; instead, on March 19, 2026 the company cancelled a set of existing stock options and granted replacement (repriced) options. The filing records dispositions to the issuer (D) totaling 1,992,203 option units and matching grants/awards (A) totaling 1,992,203 option units.
  • The repriced options set the per-share exercise price at $0.45 (effective March 19, 2026). The Form 4 reports derivative transactions (options) and does not show cash proceeds or a share-for-share sale price (price and total value shown as N/A).

Key Details

  • Transaction date: March 19, 2026; Form 4 filed March 20, 2026 (timely).
  • Transaction codes: D = disposition to issuer (old options cancelled), A = grant/award (new repriced options).
  • Total options affected: 1,992,203 canceled and 1,992,203 repriced/granted.
  • New exercise price: $0.45 per share (per footnote F1).
  • Vesting: Unchanged and governed by the original award agreements; new options vest per the previously reported schedules and require continued service (footnote F2).
  • Shares owned after transaction: Not specified in this filing.
  • Filing timeliness: No late filing indicated.

Context

  • This is a derivative repricing (administrative amendment of option strike price), not an open-market purchase or sale of shares. No shares were reported as exercised or sold to the market in this filing. Repricings are routine corporate actions to modify option economics; they do not by themselves indicate insider buying or selling of stock.

Insider Transaction Report

Form 4
Period: 2026-03-19
Gossamer Bio, Inc.GOSS
Peterson Caryn
EVP, Regulatory Affairs
Transactions
  • Disposition to Issuer

    Stock Option (Right to Buy)

    [F1][F2]
    2026-03-19−506,250→ 0 total
    Exercise: $2.88Exp: 2036-01-01→ Common Stock (506,250 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    [F1][F2]
    2026-03-19−440,000→ 0 total
    Exercise: $1.13Exp: 2035-03-03→ Common Stock (440,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    [F1][F2]
    2026-03-19−375,000→ 0 total
    Exercise: $0.97Exp: 2034-01-01→ Common Stock (375,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    [F1][F2]
    2026-03-19−125,000→ 0 total
    Exercise: $0.84Exp: 2033-11-19→ Common Stock (125,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    [F1][F2]
    2026-03-19−157,500→ 0 total
    Exercise: $1.21Exp: 2033-03-19→ Common Stock (157,500 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    [F1][F2]
    2026-03-19−157,500→ 0 total
    Exercise: $2.16Exp: 2032-12-06→ Common Stock (157,500 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    [F1][F2]
    2026-03-19−126,667→ 0 total
    Exercise: $1.36Exp: 2032-01-05→ Common Stock (126,667 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    [F1][F2]
    2026-03-19−21,167→ 0 total
    Exercise: $1.36Exp: 2031-04-16→ Common Stock (21,167 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    [F1][F2]
    2026-03-19−18,834→ 0 total
    Exercise: $1.36Exp: 2031-02-25→ Common Stock (18,834 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    [F1][F2]
    2026-03-19−22,784→ 0 total
    Exercise: $1.36Exp: 2030-02-14→ Common Stock (22,784 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    [F1][F2]
    2026-03-19−9,167→ 0 total
    Exercise: $1.36Exp: 2029-12-23→ Common Stock (9,167 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    [F1][F2]
    2026-03-19−32,334→ 0 total
    Exercise: $1.36Exp: 2029-03-25→ Common Stock (32,334 underlying)
  • Award

    Stock Option (Right to Buy)

    [F1][F2]
    2026-03-19+506,250→ 506,250 total
    Exercise: $0.45Exp: 2036-01-01→ Common Stock (506,250 underlying)
  • Award

    Stock Option (Right to Buy)

    [F1][F2]
    2026-03-19+440,000→ 440,000 total
    Exercise: $0.45Exp: 2035-03-03→ Common Stock (440,000 underlying)
  • Award

    Stock Option (Right to Buy)

    [F1][F2]
    2026-03-19+375,000→ 375,000 total
    Exercise: $0.45Exp: 2034-01-01→ Common Stock (375,000 underlying)
  • Award

    Stock Option (Right to Buy)

    [F1][F2]
    2026-03-19+125,000→ 125,000 total
    Exercise: $0.45Exp: 2033-11-19→ Common Stock (125,000 underlying)
  • Award

    Stock Option (Right to Buy)

    [F1][F2]
    2026-03-19+157,500→ 157,500 total
    Exercise: $0.45Exp: 2023-03-19→ Common Stock (157,500 underlying)
  • Award

    Stock Option (Right to Buy)

    [F1][F2]
    2026-03-19+157,500→ 157,500 total
    Exercise: $0.45Exp: 2032-12-06→ Common Stock (157,500 underlying)
  • Award

    Stock Option (Right to Buy)

    [F1][F2]
    2026-03-19+126,667→ 126,667 total
    Exercise: $0.45Exp: 2032-01-05→ Common Stock (126,667 underlying)
  • Award

    Stock Option (Right to Buy)

    [F1][F2]
    2026-03-19+21,167→ 21,167 total
    Exercise: $0.45Exp: 2031-04-16→ Common Stock (21,167 underlying)
  • Award

    Stock Option (Right to Buy)

    [F1][F2]
    2026-03-19+18,834→ 18,834 total
    Exercise: $0.45Exp: 2031-02-25→ Common Stock (18,834 underlying)
  • Award

    Stock Option (Right to Buy)

    [F1][F2]
    2026-03-19+22,784→ 22,784 total
    Exercise: $0.45Exp: 2030-02-14→ Common Stock (22,784 underlying)
  • Award

    Stock Option (Right to Buy)

    [F1][F2]
    2026-03-19+9,167→ 9,167 total
    Exercise: $0.45Exp: 2029-12-23→ Common Stock (9,167 underlying)
  • Award

    Stock Option (Right to Buy)

    [F1][F2]
    2026-03-19+32,334→ 32,334 total
    Exercise: $0.45Exp: 2029-03-25→ Common Stock (32,334 underlying)
Footnotes (2)
  • [F1]Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.
  • [F2]This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.
Signature
/s/ Jeff Boerneke, Attorney-in-Fact|2026-03-20

Documents

1 file
  • 4
    wk-form4_1774038052.xmlPrimary

    FORM 4